 | Up a level |
Tutt, Andrew N J; Garber, Judy E; Kaufman, Bella; Viale, Giuseppe; Fumagalli, Debora; Rastogi, Priya; Gelber, Richard D; de Azambuja, Evandro; Fielding, Anitra; Balmaña, Judith; Domchek, Susan M; Gelmon, Karen A; Hollingsworth, Simon J; Korde, Larissa A; Linderholm, Barbro; Bandos, Hanna; Senkus, Elżbieta; Suga, Jennifer M; Shao, Zhimin; Pippas, Andrew W; ... (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England journal of medicine, 384(25), pp. 2394-2405. Massachusetts Medical Society 10.1056/NEJMoa2105215
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
